Medical inflation is outpacing premium growth across international private medical insurance, and loss ratios are feeling it. For years the standard response has been the negotiated network: discounted rates with a panel of providers. That still matters. But a discount is a floor, not a ceiling, and once a book is on good rates the marginal saving from squeezing them further is small.
The larger, more durable savings sit upstream of the invoice, in whether the care was appropriate in the first place.
Discounts reduce the price of care. Clinical challenge reduces unnecessary care.
A negotiated rate lowers what you pay for a given intervention. It does nothing about whether that intervention was indicated, whether the length of stay was justified, or whether a lower-acuity setting would have delivered the same outcome. Those questions are clinical, and answering them requires clinicians who can engage the treating team on medical necessity, not administrators applying a fee schedule.
This is where a clinically-led model earns its place: reviewing the treatment pathway as it unfolds, not auditing the bill after the fact.
The arithmetic is worth being explicit about. Suppose you negotiate a network rate from 100 to 75, a hard-won 25 per cent and about as good as discounting gets on an established book. Now suppose the same episode of care involved two nights of inpatient stay that were not clinically necessary, a repeated CT because nobody requested the images from the referring facility, and an ICU bed retained for a day after the patient no longer needed that level of care.
The discount saved 25 on the price. The clinical questions were worth considerably more than that on the volume, and they compound: the unnecessary nights carry their own pharmacy, nursing and investigation load. Discounting works on one axis. Only clinical challenge works on the other.
Where the containable cost actually sits
Across an international book the recurring patterns are consistent, and none of them appears on an invoice marked “avoidable”:
- Setting. Inpatient care delivered where day-case or ambulatory care was clinically sufficient.
- Length of stay. Discharge or step-down that lags the patient’s actual trajectory, usually because nobody is pressing for it.
- Investigation duplication. Imaging and pathology repeated on transfer between facilities, because the prior results were never requested.
- Acuity mismatch. High-dependency or intensive care beds retained after the clinical need has passed.
- Scope creep. Incidental findings investigated in full during an acute episode for something unrelated.
Every one of these is visible only to someone reading the clinical record alongside the bill, in something close to real time. That is a clinician’s job, and it cannot be done from a fee schedule or a fortnight later.
The right care, in the right place
“Cost containment” carries an unfortunate implication, that someone is trying to withhold care. Framed properly, it is the opposite. The goal is the right care, in the right place, at the right time. That is usually both the most clinically defensible option and the most cost-effective one. Repatriating a stabilised patient to an appropriate home-country bed, for instance, can improve continuity of care and reduce the cost of a prolonged overseas admission.
The objection: this sounds like rationing
It is the fair challenge, and it needs answering rather than deflecting. If a provider is incentivised to reduce spend, why would anyone trust its clinical judgement about what care is necessary?
Three things make the difference between clinical challenge and rationing.
The first is who asks. A challenge from a clinician is a clinical conversation with the treating team, conducted in clinical language, about evidence. The treating physician can push back, and where the evidence supports them they win. A challenge from a claims handler is an administrative obstacle, and it invites escalation, complaint and reputational exposure, which is also why it tends to be conceded the moment it is pushed.
The second is what is challenged. Necessity, setting and pathway are legitimate clinical questions with clinical answers. Cost is not a clinical question, and a challenge that starts from the number rather than the notes is exactly the thing the objection is worried about.
The third is whether it is written down. A decision recorded with its clinical rationale, at the point it was made, by a named clinician, can be reviewed by anybody: the insurer, the regulator, the member’s solicitor. Rationing does not survive that kind of daylight. Sound clinical reasoning does.
Make every decision defensible
None of this works if it cannot be evidenced. When an insurer or a regulator asks why a decision was made, the answer has to be documented, clinical, and auditable. That is the standard we hold on every case: the reasoning is recorded as the case progresses through Atlas, so the record is defensible by design rather than reconstructed later.
Where to start if you are not doing this
The earlier a case is seen clinically, the more of the pathway is still available to influence, so the order of value is straightforward:
- Pre-authorisation with defined scope, so what is covered is agreed against a specific indication and pathway before treatment begins rather than argued about after.
- Concurrent review on admissions past a length-of-stay threshold, which is where the setting and step-down questions get caught while they can still be changed.
- Clinical bill review after discharge, which recovers real money but is the narrowest window, because by then every decision that determined the size of the bill has already been made.
Most books start at three and work upwards. The returns run the other way.
Discounts will always be part of the picture. But the insurers protecting their loss ratios best are the ones pairing them with genuine clinical governance over what care happens at all, and, increasingly, with clinical intelligence gathered before the claim exists.
